Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Oasmia Pharmaceutical AB (publ)
  6. News
  7. Summary
    OASM   SE0000722365

OASMIA PHARMACEUTICAL AB (PUBL)

(OASM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Oasmia Pharmaceutical AB Signs Agreement with FarmaMondo to Commercialize Paclical« in Russia & CIS

09/17/2021 | 01:00am EST

Oasmia Pharmaceutical AB announced that it has signed a license agreement with the Swiss- based FarmaMondo Group for the commercialization of Paclical® (Apealea®) in Russia and the Commonwealth of Independent States. Paclical® is the first water-soluble cancer drug with paclitaxel to receive a market authorization and is used for the treatment of for epithelial ovarian cancer, fallopian tube cancer and peritoneal cancer. Under the terms of the agreement, the marketing authorizations which Oasmia holds in Russia and Kazakhstan will be transferred to FarmaMondo. FarmaMondo will also be responsible for all future development and commercialization activities in Russia and the Commonwealth of Independent States, which includes Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Russia, Tajikistan, and Uzbekistan. Oasmia will supply FarmaMondo with Paclical® and will receive product supply revenues. The signing of this agreement heralds the completion of the out-licensing of Apealea globally and Oasmia anticipates starting to receive royalties from these partnerships during 2022.


ę S&P Capital IQ 2021
All news about OASMIA PHARMACEUTICAL AB (PUBL)
12/03Oasmia Pharmaceutical AB Announces Appointment of Nomination Committee
CI
12/02Nomination Committee appointed for the 2022 Annual General Meeting in Oasmia
AQ
11/29Oasmia to present at Stora Aktiedagen Stockholm on December 2
AQ
11/29Oasmia to present at the Erik Penser Bank Life Science Day on December 2
AQ
11/26Oasmia to present at the Erik Penser Bank Life Science Day on December 2
AQ
11/26Oasmia to present at Stora Aktiedagen Stockholm on December 2
AQ
11/18Oasmia Pharmaceutical AB Reports Earnings Results for the Third Quarter and Nine Months..
CI
11/12Invitation to presentation of Oasmia's Q3 report on November 18
AQ
11/11Invitation to presentation of Oasmia's Q3 report on November 18
AQ
10/21OASMIA PHARMACEUTICAL : announces global settlement of all disputes with MGC Capital, form..
AQ
More news
Financials
Sales 2021 10,2 M 1,12 M 1,12 M
Net income 2021 -173 M -18,9 M -18,9 M
Net cash 2021 130 M 14,2 M 14,2 M
P/E ratio 2021 -5,23x
Yield 2021 -
Capitalization 938 M 102 M 103 M
EV / Sales 2021 79,2x
EV / Sales 2022 23,3x
Nbr of Employees 26
Free-Float 61,9%
Chart OASMIA PHARMACEUTICAL AB (PUBL)
Duration : Period :
Oasmia Pharmaceutical AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OASMIA PHARMACEUTICAL AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 2,09 SEK
Average target price 5,70 SEK
Spread / Average Target 173%
EPS Revisions
Managers and Directors
Franšois R. Martelet Chief Executive Officer
Fredrik Jńrrsten Chief Financial Officer
Karl Anders Olof Hńrfstrand Independent Non-Executive Chairman
Heidi B. Ramstad Chief Medical Officer
Reinhard Koenig Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
OASMIA PHARMACEUTICAL AB (PUBL)-48.06%102
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641